Kala Pharmaceuticals Inc (OQ:KALA)

Business Focus: Pharmaceuticals

Sector:  Healthcare Industry:  Pharmaceuticals
See Regulatory Filings on SEC
Company Contact
Address: 490 ARSENAL WAY, SUITE 120
Tel: 1-212-3621200
Website: kalarx.com
IR: See website
Key People
Mark T. Iwicki
Chairman of the Board, President, Chief Executive Officer
Mary Reumuth
Chief Financial Officer, Treasurer
Todd M. Bazemore
Chief Operating Officer
Hongming Chen
Chief Scientific Officer
Eric L. Trachtenberg
Chief Compliance Officer, General Counsel, Secretary
Kim Brazzell
Chief Medical Officer
Business Overview
Kala Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company's initial focus is on the treatment of eye diseases. The Company's product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program. The Company has completed two Phase III clinical trials for KPI-121 1% . The KPI-121 0.25% is the Company's product candidate for temporary relief of signs and symptoms of dry eye disease. KPI-121 1% is the twice-a-day product candidate for treatment of post-operative inflammation and pain following ocular surgery. MPP rTKI Program is therapies for retinal diseases that should be injected directly into the patient's eye, often at monthly intervals.
Financial Overview
For the nine months ended 30 September 2020, KalaPharmaceuticals Inc revenues decreased 16% to $4.1M. Netloss increased 1% to $73.2M. Revenues reflect a decrease indemand for the Company's products and services due tounfavorable market conditions. Higher net loss reflectsGeneral and administrative - Balancing v increase of 5% to$47.7M (expense), Stock-Based Compensation increase of 32%to $6.9M (expense).
Employees: 136 as of Dec 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $336.21M as of Sep 30, 2020
Annual revenue (TTM): $5.30M as of Sep 30, 2020
EBITDA (TTM): -$86.54M as of Sep 30, 2020
Net annual income (TTM): -$95.17M as of Sep 30, 2020
Free cash flow (TTM): -$84.63M as of Sep 30, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 56,075,211 as of Nov 4, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.